{"id":4677,"date":"2026-06-04T20:44:48","date_gmt":"2026-06-05T00:44:48","guid":{"rendered":"https:\/\/mivado.com\/mgp\/?p=4677"},"modified":"2026-06-04T20:50:59","modified_gmt":"2026-06-05T00:50:59","slug":"gmp-tacit-knowledge-gap-in-tech-transfer","status":"publish","type":"post","link":"https:\/\/mivado.com\/mgp\/gmp-tacit-knowledge-gap-in-tech-transfer\/","title":{"rendered":"Solving the Tacit Knowledge Gap in Pharmaceutical Tech Transfer"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_column_text css=&#8221;&#8221;]<\/p>\n<h5>Beyond Documentation: Solving the Tacit Knowledge Gap in Pharmaceutical Tech Transfer: Why Your Documentation Is Not Enough and How to Institutionalize Expert Know-How.<\/h5>\n<p>[\/vc_column_text][vc_column_text css=&#8221;&#8221;]In the high-stakes world of pharmaceutical manufacturing, technology transfer is often viewed through the lens of rigid documentation, master batch records, analytical methods, and validation protocols. Yet, despite having exhaustive paper trails, many projects suffer from unexpected delays, process variability, and quality deviations.\u00a0(1).<\/p>\n<p>The culprit is rarely a flaw in the paperwork itself. It is the silent, pervasive gap in tacit knowledge, the &#8220;unwritten&#8221; experience-based know-how that lives exclusively in the minds of your technical experts.<\/p>\n<h2>The Hidden Risk of &#8220;Paper-Only&#8221; Transfers<\/h2>\n<p>Tacit knowledge is inherently personal. It includes the \u201ctroubleshooting intuition\u201d of a veteran operator who knows exactly how a piece of equipment sounds when it\u2019s running optimally. It also encompasses the historical context behind a specific process deviation that isn\u2019t recorded in the official archives.\u00a0(2).<\/p>\n<p>When technology transfer relies solely on codified documentation, you are essentially asking the receiving team to learn an entire craft from a textbook. This perspective overlooks the reality that in complex GMP environments, expert performance often arises from \u201cindwelling,\u201d meaning the ability to intuitively perceive and respond to subtle process cues that cannot be fully captured in a standard operating procedure (SOP). Relying on documents alone is a high-risk strategy that often leads to increased training times, lower yields, and recurring quality issues during scale-up. However, if the Receiving Unit (RU) identifies particular problems with the process during the transfer, it should communicate these issues back to the Sending Unit (SU) to ensure ongoing knowledge management (3).<\/p>\n<h2>The Human-to-Human Advantage<\/h2>\n<p>To truly de-risk your technology transfer, you must move beyond the &#8220;document-handover&#8221; mindset. The highest-leverage approach integrates human-to-human transfer mechanisms, which act as the bridge between explicit documentation and operational mastery.<\/p>\n<h3>1- Strategic Secondments and Shadowing<\/h3>\n<p>Placing key staff from the sending unit directly into the receiving unit or vice versa is the gold standard for transferring nuanced process knowledge. Shadowing allows receiving team members to observe how critical process parameters (CPPs) are managed in real-time, providing an opportunity to ask the &#8220;why&#8221; behind the &#8220;how.&#8221; It turns passive learning into an active, observational experience.<\/p>\n<h3>2- Communities of Practice (CoPs)<\/h3>\n<p>CoPs represent a powerful, sustainable way to manage knowledge beyond the project lifecycle. By bringing together subject matter experts from cross-functional teams, these communities provide a safe space for practitioners to share troubleshooting tips, discuss deviations, and refine methods. Unlike formal training, which is often transactional, CoPs foster a culture of collective intelligence, ensuring that lessons learned in one department or facility are disseminated throughout the organization.<\/p>\n<h3>3- Mentorship and Structured Reflection<\/h3>\n<p>Formalizing mentorship roles ensures that tacit knowledge is not lost when senior staff retire or rotate. Incorporating structured reflection sessions after key transfer milestones, where teams explicitly discuss what they learned beyond what was written in the reports, creates a cycle of continuous improvement that strengthens the organization&#8217;s overall competency.<\/p>\n<h2>Bridging the Gap<\/h2>\n<p>At the intersection of regulatory compliance and operational excellence, successful technology transfer is not just about meeting the requirements of a GMP audit. It is about building a robust, knowledge-enabled workforce that can navigate complexity with confidence.<\/p>\n<p>Documentation is necessary for compliance, but a human-to-human connection is essential for performance. By operationalizing these human-centric strategies, you reduce your reliance on trial and error and shorten the time-to-market for critical healthcare products.[\/vc_column_text][vc_column_text css=&#8221;&#8221;]<\/p>\n<h2>References<\/h2>\n<p>1- Upperton; Navigating Technology Transfer in Pharmaceutical Manufacturing: Best Practices, https:\/\/upperton.com\/navigating-technology-transfer-in-pharmaceutical-manufacturing-best-practices\/<\/p>\n<p>2- Dr. Lars Lueersen. Knowledge Management, GMP Journal; 15.05.2019; https:\/\/www.gmp-journal.com\/current-articles\/details\/knowledge-management.html#:~:text=3%2C4,and%20experiences%20of%20the%20individual.<\/p>\n<p>3- <a href=\"https:\/\/www.who.int\/publications\/m\/item\/trs1044-annex4\" target=\"_blank\" rel=\"noopener\">WHO Guidelines on Technology Transfer in Pharmaceutical Manufacturing; TRS 1044, Annex 4<\/a><\/p>\n<p>4- <a href=\"https:\/\/mivado.com\/mgp\/navigating-msat-for-successful-technology-transfer\/\">Navigating the Pitfalls of MSAT for Successful Technology Transfer | Mivado GlobalPerformance<\/a>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_cta h2=&#8221;Ready to Transform Your Tech Transfer Strategy?&#8221; h4=&#8221;Is your organization struggling to capture the tacit expertise necessary to scale processes safely and efficiently?&#8221; add_button=&#8221;bottom&#8221; btn_title=&#8221;Send your Request Today !&#8221; btn_color=&#8221;blue&#8221; btn_i_icon_fontawesome=&#8221;fa fa-solid fa-calendar&#8221; btn_css_animation=&#8221;zoomIn&#8221; add_icon=&#8221;left&#8221; css_animation=&#8221;zoomIn&#8221; css=&#8221;&#8221; btn_add_icon=&#8221;true&#8221; btn_link=&#8221;url:https%3A%2F%2Fmivado.com%2Feshop%2Fappointement-page%2F|target:_blank&#8221;]We specialize in helping pharmaceutical and life science companies modernize their knowledge management systems and implement high-leverage human-to-human transfer frameworks.<\/p>\n<p><a href=\"https:\/\/mivado.com\/mgp\/technology-transfer-by-design\/\" target=\"_blank\" rel=\"noopener\">Subscribe to our expert consulting services today<\/a> to gain access to proprietary audit toolkits, CoP development roadmaps, and personalized coaching for your technical transfer teams. Let\u2019s turn your organization\u2019s hidden experience into your greatest competitive advantage.[\/vc_cta][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Beyond Documentation: Solving the Tacit Knowledge Gap in Pharmaceutical Tech Transfer: This article discuss  why Your Documentation Is Not Enough and How to Institutionalize Expert Know-How.  Visit us for more&#8230;<\/p>\n","protected":false},"author":2,"featured_media":4708,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[198,6,163,10],"tags":[168,41,21,129,20,13],"class_list":["post-4677","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-msat-tt","category-operational-excellence","category-process-improvement","category-risk-management","tag-biopharmaceutical","tag-gxp","tag-pharma-4-0","tag-quality","tag-quality-4-0","tag-risk-management"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/mivado.com\/mgp\/wp-content\/uploads\/2026\/06\/MGP-Knowledge-Gap-EN-scaled.png?fit=2560%2C1280&ssl=1","wps_subtitle":"","_links":{"self":[{"href":"https:\/\/mivado.com\/mgp\/wp-json\/wp\/v2\/posts\/4677","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mivado.com\/mgp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mivado.com\/mgp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mivado.com\/mgp\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mivado.com\/mgp\/wp-json\/wp\/v2\/comments?post=4677"}],"version-history":[{"count":20,"href":"https:\/\/mivado.com\/mgp\/wp-json\/wp\/v2\/posts\/4677\/revisions"}],"predecessor-version":[{"id":4716,"href":"https:\/\/mivado.com\/mgp\/wp-json\/wp\/v2\/posts\/4677\/revisions\/4716"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mivado.com\/mgp\/wp-json\/wp\/v2\/media\/4708"}],"wp:attachment":[{"href":"https:\/\/mivado.com\/mgp\/wp-json\/wp\/v2\/media?parent=4677"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mivado.com\/mgp\/wp-json\/wp\/v2\/categories?post=4677"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mivado.com\/mgp\/wp-json\/wp\/v2\/tags?post=4677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}